Fatty acid binding proteins as drug targets for endocannabinoids
The invention provides a method of modulating the level of an endocannabinoid in a subject in need thereof comprising administering an effective amount of an agent that inhibits the interaction of the endocannabinoid with an intracellular fatty acid binding protein (FABP). The invention also provides a method of identifying an agent for modulating the level of an endocannabinoid in a subject comprising testing the agent for its ability to modulate binding of the endocannabinoid with an intracellular FABP. The invention also provides a method of identifying an agent for modulating the level of an endocannabinoid in a subject comprising testing the agent for its ability to modulate expression of an intracellular FABP. The invention also provides a method of identifying an agent for treatment of a neurological disorder comprising testing the agent for its ability to modulate the interaction of an endocannabinoid with an intracellular FABP. The invention also relates to modulation of levels of fatty acid amides for treatment or amelioration of diseases or disorders by modulating binding of the fatty acid amides to fatty acid binding proteins. In one embodiment, the fatty acid binding protein is one or more of FABP3, FABP5, and FABP7. In one embodiment, the level of an endocannabinoid is modulated.
1. A method of increasing the level of an endocannabinoid in a subject in need thereof comprising administering to the subject an effective amount of an agent that inhibits the binding of the endocannabinoid with fatty acid binding protein 5 (FABP5) in the subject.
2. The method of claim 1 , wherein the level of the endocannabinoid is increased in the CNS.
3. The method of claim 1 , wherein the endocannabinoid is 2 arachidonoylglycerol (2-AG).
4. The method of claim 1 , wherein the endocannabinoid is anandamide (AEA).
5. The method of claim 1 , wherein the increase in the level of the endocannabinoid treats or ameliorates a neurological disorder.
6. The method of claim 1 , wherein the agent is BMS-309403 or BMS-480404.
7. The method of claim 1 , wherein the subject is a human.
8. The method of claim 5 , wherein the neurological disorder affects at least one of movement, memory, mood, appetite, nociception, endocrine regulation, thermoregulation, sensory perception, and cognitive functions.
9. The method of claim 5 , wherein the neurological disorder is drug addiction, depression, compulsive behavior, neuropathic pain, or a movement disorder.
10. A method of increasing the level of an endocannabinoid in a subject in need thereof comprising administering to the subject an effective amount of an agent that inhibits the binding of the endocannabinoid with fatty acid binding protein 7 (FABP7) in the subject.
11. The method of claim 10 , wherein the level of the endocannabinoid is increased in the CNS.
12. The method of claim 10 , wherein the endocannabinoid is 2-arachidonoylglycerol (2-AG).
13. The method of claim 10 , wherein the endocannabinoid is anandamide (AEA).
14. The method of claim 10 , wherein the increase in the level of the endocannabinoid treats or ameliorates a neurological disorder.
15. The method of claim 10 , wherein the agent is BMS-309403 or BMS-480404.
16. The method of claim 14 , wherein the neurological disorder affects at least one of movement, memory, mood, appetite, nociception, endocrine regulation, thermoregulation, sensory perception, and cognitive functions.
17. The method of claim 14 , wherein the neurological disorder is drug addiction, depression, compulsive behavior, neuropathic pain, or a movement disorder.
18. The method of claim 14 , wherein the subject is a human.